NDLI: Comparative analysis of different response criteria at early phase after PD-1 blockade in non-small lung cancer

Content Provider	Springer Nature : BioMed Central
Author	Kaira, Kyoichi Yamaguchi, Ou Naruse, Ichiro Umeda, Yukihiro Honda, Takeshi Watanabe, Satoshi Ichikawa, Kosuke Yanagisawa, Shin Kasahara, Norimitsu Higuchi, Tetsuya Hashimoto, Kosuke Miura, Yu Shiono, Ayako Mouri, Atsuto Imai, Hisao Iizuka, Kunihiko Ishizuka, Tamotsu Minato, Koichi Suda, Satoshi Kagamu, Hiroshi Mori, Keita Seki, Nobuhiko Kuji, Ichiei
Abstract	Purpose To compare different response criteria using computed tomography (CT) and positron emission tomography (PET) in measuring response and survival in the early phase after programmed death-1 (PD-1) blockade monotherapy in patients with advanced non-small cell lung cancer (NSCLC). Methods A total of 54 patients with advanced NSCLC who had 2-deoxy-2-[fluorine-18]-fluoro-D-glucose PET or CT at baseline, and 4 and 9 weeks after PD-1 blockade, were registered. Therapeutic response was assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST), the immune-modified RECIST (irRECIST), the PET Response Criteria in Solid Tumors (PERCIST), the immune-modified PERCIST (iPERCIST), and the European Organization for Research and Treatment of Cancer (EORTC) criteria for dichotomous groups, such as responders vs. non-responders and controlled vs. uncontrolled diseases. Cohen’s κ was used to evaluate the concordance among the different criteria. Results The concordance between CT and PET response criteria was fair or slight for responders vs. non-responders, but the agreement between iPERCIST and irRECIST was moderate for controlled vs. uncontrolled diseases. The agreement between EORTC and PERCIST or iPERCIST in detecting responders was higher in the application of metabolic tumor volume (MTV) and total lesion glycolysis (TLG) than in the standardized uptake value corrected for lean body mass (SUL)peak. To distinguish controlled from uncontrolled disease, RECIST, irRECIST, and PET criteria (PERCIST, iPERCIST, and EORTC) defined by MTV or TLG were found to be significant predictors of progression-free survival. To distinguish responders from non-responders, iPERCIST by SULpeak or EORTC by TLG were identified as significant indicators. The EORTC criteria using TLG for the detection of responders or uncontrolled diseases had a significantly higher predictive value for response assessment. Conclusions The EORTC criteria based on TLG for the early detection of responders and uncontrolled disease were effective as a response assessment at 4 weeks after the PD-1 blockade. When SULpeak was not used but MTV or TLG was, the agreement between EORTC and PERCIST or iPERCIST was almost perfect.
Related Links	https://cancerimagingjournal.biomedcentral.com/counter/pdf/10.1186/s40644-023-00538-x.pdf
Ending Page	13
Page Count	13
Starting Page	1
File Format	HTM / HTML
ISSN	14707330
DOI	10.1186/s40644-023-00538-x
Journal	Cancer Imaging
Issue Number	1
Volume Number	23
Language	English
Publisher	BioMed Central
Publisher Date	2023-03-01
Access Restriction	Open
Subject Keyword	Oncology Cancer Research Imaging Radiology Nuclear Medicine 18F-FDG PET PD-1 blockade Immunotherapy Lung cancer Early response PET response criteria
Content Type	Text
Resource Type	Article
Subject	Radiological and Ultrasound Technology Radiology, Nuclear Medicine and Imaging Oncology
Journal Impact Factor	3.5/2023
5-Year Journal Impact Factor	4.3/2023

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Value of 18F-FDG-PET to predict PD-L1 expression and outcomes of PD-1 inhibition therapy in human cancers

The utility of 18F-FDG PET/CT for predicting the pathological response and prognosis to neoadjuvant immunochemotherapy in resectable non-small-cell lung cancer

Interim [¹⁸F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma.

Additional value of 18F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer

Correction: The utility of 18F-FDG PET/CT for predicting the pathological response and prognosis to neoadjuvant immunochemotherapy in resectable non-small-cell lung cancer

The efficiency of 18F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer

[18F]FAPI adds value to [18F]FDG PET/CT for diagnosing lymph node metastases in stage I-IIIA non-small cell lung cancer: a prospective study

Early post-treatment 18F-FDG PET/CT for predicting radiation-induced hypothyroidism in head and neck cancer

Chemotherapy response evaluation in metastatic non-small cell lung carcinoma (NSCLC) with 18F- FDG PET/CT and CT scan

Comparative analysis of different response criteria at early phase after PD-1 blockade in non-small lung cancer

Similar Documents

Value of 18F-FDG-PET to predict PD-L1 expression and outcomes of PD-1 inhibition therapy in human cancers

The utility of 18F-FDG PET/CT for predicting the pathological response and prognosis to neoadjuvant immunochemotherapy in resectable non-small-cell lung cancer

Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma.

Additional value of 18F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer

Correction: The utility of 18F-FDG PET/CT for predicting the pathological response and prognosis to neoadjuvant immunochemotherapy in resectable non-small-cell lung cancer

The efficiency of 18F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer

[18F]FAPI adds value to [18F]FDG PET/CT for diagnosing lymph node metastases in stage I-IIIA non-small cell lung cancer: a prospective study

Early post-treatment 18F-FDG PET/CT for predicting radiation-induced hypothyroidism in head and neck cancer

Chemotherapy response evaluation in metastatic non-small cell lung carcinoma (NSCLC) with 18F- FDG PET/CT and CT scan

Comparative analysis of different response criteria at early phase after PD-1 blockade in non-small lung cancer

Interim [¹⁸F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma.